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  EVIDENCE-BASED ANSWER 
Glucosamine may provide some pain relief. Studies have shown varied results, ranging from glucosamine 
being superior or equivalent to other agents, to no difference between glucosamine and placebo. However, 
most of these studies have small sample sizes, short duration, and often other significant flaws. Meta-analyses 
of available studies suggest a trend toward benefit from glucosamine (strength of recommendation: B). 
Glucosamine may help osteoarthritis pain, but it is premature to recommend it universally until better studies 
are done. Even if glucosamine is effective, this sector of the market is currently unregulated, and products may 
not contain the amount or kind of glucosamine material advertised on their labels. 
  EVIDENCE SUMMARY 
Multiple methodological flaws have characterized studies trying to answer this question over the past 30 to 35 
years. The companies manufacturing glucosamine have funded most studies. The overwhelming proportion of 
positive but marginal results raises the possibility of a publication bias (the tendency to publish only positive or 
supportive results), and the funding sources for the positive studies make that bias plausible. 
Identified flaws in the studies include small sample size, inconsistent diagnostic criteria, variable disease sites, 
differing routes of administration, inconsistent doses, compositions and forms of glucosamine, the brief 
durations of studies, and poorly defined endpoints.1 Those problems account for the relatively low quality 
scores of the studies used in meta-analyses, particularly in earlier ones. Quality scores range from 12% to 52% 
of optimal and make any definitive conclusions suspect.2 
The magnitude of the treatment effect is variable. Meta-analyses demonstrate aggregate treatment effects 
ranging from 0.36 to 1.02— where a small effect is 0.2, a moderate effect is 0.5, and a large effect is 0.8.2 
When more recent, higher-quality studies are analyzed, trends toward benefit and the effect sizes for 
glucosamine diminish but remain at aggregate values ranging from 0.26 to 0.44.2-4 Statistically significant 
differences exist in some subgroup analyses and secondary endpoints.5 Typical trends suggest that 
glucosamine is superior to placebo for pain relief, and less effective but safer than nonsteroidal anti-
inflammatory agents.6 
Statements about safety are speculative given the brief duration of available trials, most of which lasted <10 
weeks.6 Reported adverse effects are few. Mild gastrointestinal, skin, and constitutional symptoms 
predominate, but seldom at rates much higher than placebo.3-4 Pain relief may require as much as 4 to 6 
weeks of therapy, and short studies may not demonstrate these benefits. The possibility of site-specific 
benefits or a difference in effect from a different dose or form is impossible to determine based on the current 
literature. 
  RECOMMENDATIONS FROM OTHERS 
The American College of Rheumatology Subcommittee on Osteoarthritis believes that it is too early to issue 
recommendations for use of glucosamine sulfate or chondroitin sulfate for treatment of osteoarthritis.7 
The National Institutes of Health Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) began recruiting in 
May 2002. The design of this study is specifically directed at addressing the flaws of previous studies. This 
study will enroll 1588 patients at 13 study sites, and will use standardized products and doses with a single 
route of administration in a double-blinded, placebo-controlled fashion. 
The GAIT study will measure change in joint space width (baseline to 2 years) and consists of 4 arms: 
glucosamine vs placebo, chondroitin vs placebo, glucosamine and chondroitin vs placebo, and celecoxib vs 
placebo. It is likely that the National Institute of Arthritis, Musculoskeletal and Skin Diseases, in collaboration 
with the National Center for Complementary and Alternative Medicine, will issue recommendations regarding 
the efficacy of glucosamine when the study is complete in 2005 or 2006. Updates are available at 
http://nccam.nih.gov/clinicaltrials/ glucosamine.htm. 
CLINICAL COMMENTARY 
Russell  W.  Roberts,  MD 
Louisiana State University Health Sciences Center,Shreveport, La 
Patients frequently ask me if glucosamine, in combination with chondroitin or 
methylsulfonylmethane (MSM), reduces or prevents arthritis pain. It appears that 
glucosamine is safe and offers some promise. 
I think a 6-week trial in patients with osteoarthritis is reasonable, preferably using 
glucosamine—a type that complies with the United States Pharmacopia/National 
Formulary standards—500 mg orally 3 times daily, once it becomes widely available. In 
my experience, very few patients who give glucosamine an enthusiastic and adequate trial 
of therapy continue the course for more than a few months. Those who use it longer often 
acknowledge only modest relief but continue with the hope of preventing further joint 
degeneration and increased pain, another currently unsubstantiated expectation. 
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